dc.contributor.author |
Vaid, Pooja M. |
en_US |
dc.contributor.author |
SHASHIDHARA, L. S. et al. |
en_US |
dc.date.accessioned |
2022-12-09T05:55:58Z |
|
dc.date.available |
2022-12-09T05:55:58Z |
|
dc.date.issued |
2022-12 |
en_US |
dc.identifier.citation |
Diagnostic Pathology, 17, 91. |
en_US |
dc.identifier.issn |
1746-1596 |
en_US |
dc.identifier.uri |
https://doi.org/10.1186/s13000-022-01271-y |
en_US |
dc.identifier.uri |
http://dr.iiserpune.ac.in:8080/xmlui/handle/123456789/7488 |
|
dc.description.abstract |
Objectives
Evaluation of tumor-infiltrating lymphocytes (TILs) distribution in an Indian cohort of breast cancer patients for its prognostic significance.
Methods
A retrospective cohort of breast cancer patients from a single onco-surgeon’s breast cancer clinic with a uniform treatment strategy was evaluated for TILs. Tumor sections were H&E stained and scored for the spatial distribution and percent stromal TILs infiltration by a certified pathologist. The scores were analysed for association with treatment response and survival outcomes across molecular subtypes.
Results
Total 229 breast cancer tumors were evaluated. Within spatial distribution categories, intra-tumoral TILs were observed to be associated with complete pathological response and lower recurrence frequency for the entire cohort. Subtype-wise analysis of stromal TILs (sTILs) re-enforced significantly higher infiltration in TNBC compared to HER2-positive and ER-positive tumors. A favourable association of higher stromal infiltration was observed with treatment response and disease outcomes, specifically in TNBC.
Conclusion
Intra-tumoral TILs showed a higher proportion with favourable association with better patient outcomes in an Indian cohort, unlike western cohorts where both stromal and intra-tumoral TILs show similar association with prognosis. With further validation, TILs can be developed as a cost-effective surrogate marker for treatment response, especially in a low-resource setting such as India. |
en_US |
dc.language.iso |
en |
en_US |
dc.publisher |
BioMed Central Ltd |
en_US |
dc.subject |
TILs |
en_US |
dc.subject |
TNBC |
en_US |
dc.subject |
Breast Cancer in India |
en_US |
dc.subject |
2022-DEC-WEEK1 |
en_US |
dc.subject |
TOC-DEC-2022 |
en_US |
dc.subject |
2022 |
en_US |
dc.title |
Evaluation of tumor-infiltrating lymphocytes (TILs) in molecular subtypes of an Indian cohort of breast cancer patients |
en_US |
dc.type |
Article |
en_US |
dc.contributor.department |
Dept. of Biology |
en_US |
dc.identifier.sourcetitle |
Diagnostic Pathology |
en_US |
dc.publication.originofpublisher |
Foreign |
en_US |